Industry Strength Score
31/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
HLS THERAPEUTICS INC (HLS.CA) Stock Price & Overview
TSX:HLS • CA40390B1094
Current stock price
4.65 CAD
-0.04 (-0.85%)
Last:
The current stock price of HLS.CA is 4.65 CAD. Today HLS.CA is down by -0.85%. In the past month the price increased by 6.41%. In the past year, price increased by 5.68%.
HLS.CA Key Statistics
52-Week Range4.22 - 5.765
Current HLS.CA stock price positioned within its 52-week range.
1-Month Range4.3 - 4.81
Current HLS.CA stock price positioned within its 1-month range.
- Market Cap
- 145.406M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.53
- Dividend Yield
- N/A
HLS.CA Stock Performance
Today
-0.85%
1 Week
N/A
1 Month
+6.41%
3 Months
+3.56%
Longer-term
6 Months -16.67%
1 Year +5.68%
2 Years N/A
3 Years -16.96%
5 Years -76.09%
10 Years N/A
HLS.CA Stock Chart
HLS.CA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to HLS.CA. When comparing the yearly performance of all stocks, HLS.CA turns out to be only a medium performer in the overall market: it outperformed 40.48% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
HLS.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to HLS.CA. While HLS.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
HLS.CA Earnings
On March 12, 2026 HLS.CA reported an EPS of -0.04 and a revenue of 15.20M. The company missed EPS expectations (-32.01% surprise) and beat revenue expectations (0.3% surprise).
Next Earnings DateMay 7, 2026
Last Earnings DateMar 12, 2026
PeriodQ4 / 2025
EPS Reported-$0.04
Revenue Reported15.195M
EPS Surprise -32.01%
Revenue Surprise 0.30%
HLS.CA Forecast & Estimates
8 analysts have analysed HLS.CA and the average price target is 8.27 CAD. This implies a price increase of 77.95% is expected in the next year compared to the current price of 4.65.
For the next year, analysts expect an EPS growth of 6.77% and a revenue growth 5.52% for HLS.CA
Analysts
Analysts80
Price Target8.27 (77.85%)
EPS Next Y6.77%
Revenue Next Year5.52%
HLS.CA Financial Highlights
Over the last trailing twelve months HLS.CA reported a non-GAAP Earnings per Share(EPS) of -0.53. The EPS increased by 37.1% compared to the year before.
Income Statements
Revenue(TTM)55.50M
Net Income(TTM)-12.43M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -9.04% | ||
| ROE | -20.16% | ||
| Debt/Equity | 0.73 |
Chartmill High Growth Momentum
EPS Q2Q%60%
Sales Q2Q%-2.23%
EPS 1Y (TTM)37.1%
Revenue 1Y (TTM)-1.98%
HLS.CA Ownership
Ownership
Inst Owners43.33%
Shares31.27M
Float31.11M
Ins Owners0.53%
Short Float %N/A
Short RatioN/A
HLS.CA Industry Overview
HLS.CA operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 29 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
48/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
39%
Outperformed 39% of sub-industries
3 Month Rank
62%
Outperformed 62% of sub-industries
6 Month Rank
25%
Outperformed 25% of sub-industries
Industry Fundamentals & Breadth
- Members
- 29
- New Highs
- 3.5%
- New Lows
- 10.3%
- Average ROE
- 17.4%
- Average Profit Margin
- 10%
- Average Operating Margin
- 19.1%
- Average P/E
- 5.3
- Average Fwd P/E
- 17.6
- Average Debt/Equity
- 0.5
HLS.CA Competitors/Peers
The largest stocks on the Canadian markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| BHC | BAUSCH HEALTH COS INC | 1.32 | 2.909B | ||
| CRON | CRONOS GROUP INC | 39.95 | 1.362B | ||
| TLRY | TILRAY BRANDS INC | N/A | 987.178M | ||
| DHT-UN | DRI HEALTHCARE TRUST | 5.19 | 894.075M | ||
| GUD | KNIGHT THERAPEUTICS INC | 43.68 | 735.225M | ||
| WEED | CANOPY GROWTH CORP | N/A | 688.379M | ||
| CPH | CIPHER PHARMACEUTICALS INC | 17.22 | 447.709M | ||
| TSND | TERRASCEND CORP | N/A | 386.797M | ||
| HITI | HIGH TIDE INC | 15.61 | 290.949M | ||
| ACB | AURORA CANNABIS INC | 57.8 | 264.836M | ||
| OGI | ORGANIGRAM GLOBAL INC | 28.02 | 260.409M | ||
| CRDL | CARDIOL THERAPEUTICS INC-A | N/A | 207.985M | ||
| XLY | AUXLY CANNABIS GROUP INC | 14.36 | 203.731M |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About HLS.CA
Company Profile
HLS Therapeutics, Inc. engages in commercializing pharmaceutical products. The company is headquartered in Etobicoke, Ontario and currently employs 86 full-time employees. The company is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Company Info
IPO: 1980-03-17
HLS THERAPEUTICS INC
10 Carlson Court, Suite 701
Etobicoke ONTARIO M9W 6L2 CA
CEO: Christopher Nutt
Employees: 85
Phone: 16474959000
HLS THERAPEUTICS INC / HLS.CA FAQ
Can you describe the business of HLS THERAPEUTICS INC?
HLS Therapeutics, Inc. engages in commercializing pharmaceutical products. The company is headquartered in Etobicoke, Ontario and currently employs 86 full-time employees. The company is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
What is the current price of HLS stock?
The current stock price of HLS.CA is 4.65 CAD. The price decreased by -0.85% in the last trading session.
Does HLS THERAPEUTICS INC pay dividends?
HLS.CA does not pay a dividend.
How is the ChartMill rating for HLS THERAPEUTICS INC?
HLS.CA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is HLS.CA stock listed?
HLS.CA stock is listed on the Toronto Stock Exchange exchange.
What is the market capitalization of HLS stock?
HLS THERAPEUTICS INC (HLS.CA) has a market capitalization of 145.41M CAD. This makes HLS.CA a Micro Cap stock.
What is the next earnings date for HLS stock?
HLS THERAPEUTICS INC (HLS.CA) will report earnings on 2026-05-07.